Manchester, UK 10 September 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that a Contract Award Notice has been published in relation to its contract with the
Verona Pharma plc (LON:VRP) Positive Top-line Data in 4 Week Phase 2b COPD Study.
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function